Zejing Pharmaceuticals (688266.SH): The application for the listing of Gefitinib hydrochloride tablets for the treatment of severe alopecia areata has been approved.

Ze Jing Pharmaceutical (688266.SH) announced that the company recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The company's independently developed Gicasitrin hydrochloride tablets for the treatment of severe adult alopecia areata have been approved for market application. This is the second approved indication for Gicasitrin hydrochloride tablets, following the approval for the treatment of intermediate to high-risk bone marrow fibrosis. It is also the first approved clinical indication for the treatment of immune-inflammatory diseases for Gicasitrin hydrochloride tablets. Gicasitrin hydrochloride (formerly known as Jacktinib hydrochloride) is a novel JAK inhibitor that has a good inhibitory effect on the four subtypes of JAK kinases: JAK1, JAK2, JAK3, and TYK2. Gicasitrin can effectively inhibit inflammation, suppress excessive T cell activation, significantly increase the thickness of the dermis, promote hair follicle regeneration, and increase hair follicle density. The approved indication in this case is severe adult alopecia areata, which is the second approved indication for Gicasitrin hydrochloride tablets and the first approved clinical indication for the treatment of immune-inflammatory diseases.